Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy data for a personalized maintenance approach using bone marrow-based MRD testing (clonoSEQ) to guide post-autologous hematopoietic cell transplant (AHCT) maintenance with elranatamab for this patient population.

Trial Details

NCT ID
NCT06483100
Phase
PHASE2
Sponsor
Washington University School of Medicine
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • Elrantamab
  • clonoSEQ
Locations (sample)
  • St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

  • At least 18 years of age
  • Ability to understand and willingness to sign an IRB approved written informed consent document. (Legally authorized representatives may sign and g…
  • Received autologous hematopoietic cell transplantation (with or without tandem transplant) as part of frontline therapy for newly diagnosed IgG or …
  • Received frontline treatment with at least a triplet regimen including a PI and an IMID (+/- an anti-CD38 antibody)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →